Avastin re-submitted to FDA

Perhaps the second time is the charm for Genentech. The biotech has re-submitted a sBLA to the FDA for Avastin in combination with paclitaxel chemotherapy as a first-line treatment for metastatic breast cancer. In September 2006 Genentech was dealt a setback when the FDA asked to see more data, including an independent review, before it would approve the new indication. Genentech supplied the additional information and the six-month FDA review process will now begin.

- here's the release on the sBLA
- read this article from Forbes

ALSO: Watch a blockbuster cancer drug become a behemoth: Roche has won European regulatory approval for treatment of advanced non-small cell lung cancer with Avastin. FiercePharma

Related Articles:
Genentech touts pipeline prospects as doubts fester. Report
Genentech fights to keep edge in drug development. Report
FDA deals setback to Genentech. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.